These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 18632651)

  • 1. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients.
    Wheeler CJ; Black KL; Liu G; Mazer M; Zhang XX; Pepkowitz S; Goldfinger D; Ng H; Irvin D; Yu JS
    Cancer Res; 2008 Jul; 68(14):5955-64. PubMed ID: 18632651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
    Wheeler CJ; Das A; Liu G; Yu JS; Black KL
    Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
    Liau LM; Prins RM; Kiertscher SM; Odesa SK; Kremen TJ; Giovannone AJ; Lin JW; Chute DJ; Mischel PS; Cloughesy TF; Roth MD
    Clin Cancer Res; 2005 Aug; 11(15):5515-25. PubMed ID: 16061868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J; Flomenberg P; Harshyne L; Kenyon L; Andrews DW
    Clin Cancer Res; 2005 Jul; 11(14):5292-9. PubMed ID: 16033848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme.
    De Vleeschouwer S; Fieuws S; Rutkowski S; Van Calenbergh F; Van Loon J; Goffin J; Sciot R; Wilms G; Demaerel P; Warmuth-Metz M; Soerensen N; Wolff JE; Wagner S; Kaempgen E; Van Gool SW
    Clin Cancer Res; 2008 May; 14(10):3098-104. PubMed ID: 18483377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of immunomodulation in human glioblastoma.
    Avril T; Vauleon E; Tanguy-Royer S; Mosser J; Quillien V
    Immunotherapy; 2011 Apr; 3(4 Suppl):42-4. PubMed ID: 21524170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration.
    Yu JS; Wheeler CJ; Zeltzer PM; Ying H; Finger DN; Lee PK; Yong WH; Incardona F; Thompson RC; Riedinger MS; Zhang W; Prins RM; Black KL
    Cancer Res; 2001 Feb; 61(3):842-7. PubMed ID: 11221866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
    Steiner HH; Bonsanto MM; Beckhove P; Brysch M; Geletneky K; Ahmadi R; Schuele-Freyer R; Kremer P; Ranaie G; Matejic D; Bauer H; Kiessling M; Kunze S; Schirrmacher V; Herold-Mende C
    J Clin Oncol; 2004 Nov; 22(21):4272-81. PubMed ID: 15452186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma.
    Chang CN; Huang YC; Yang DM; Kikuta K; Wei KJ; Kubota T; Yang WK
    J Clin Neurosci; 2011 Aug; 18(8):1048-54. PubMed ID: 21715171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
    Yajima N; Yamanaka R; Mine T; Tsuchiya N; Homma J; Sano M; Kuramoto T; Obata Y; Komatsu N; Arima Y; Yamada A; Shigemori M; Itoh K; Tanaka R
    Clin Cancer Res; 2005 Aug; 11(16):5900-11. PubMed ID: 16115932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.
    Crane CA; Han SJ; Ahn B; Oehlke J; Kivett V; Fedoroff A; Butowski N; Chang SM; Clarke J; Berger MS; McDermott MW; Prados MD; Parsa AT
    Clin Cancer Res; 2013 Jan; 19(1):205-14. PubMed ID: 22872572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
    Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
    J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1 trial of intranodal injection of a Melan-A/MART-1 DNA plasmid vaccine in patients with stage IV melanoma.
    Weber J; Boswell W; Smith J; Hersh E; Snively J; Diaz M; Miles S; Liu X; Obrocea M; Qiu Z; Bot A
    J Immunother; 2008; 31(2):215-23. PubMed ID: 18481391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma.
    Jie X; Hua L; Jiang W; Feng F; Feng G; Hua Z
    Cell Biochem Biophys; 2012 Jan; 62(1):91-9. PubMed ID: 21909820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotreatment in patients with glioblastoma multiforme--a histopathological evaluation of reactive and inflammatory changes.
    Persson A; Skagerberg G; Salford LG; Englund E;
    Clin Neuropathol; 2005; 24(5):201-8. PubMed ID: 16167543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
    Del Vecchio CA; Wong AJ
    Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
    Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
    J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine.
    Burgdorf SK; Fischer A; Myschetzky PS; Munksgaard SB; Zocca MB; Claesson MH; Rosenberg J
    Oncol Rep; 2008 Dec; 20(6):1305-11. PubMed ID: 19020707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
    Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
    Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.